A- A A+

Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment. 

Hu WL, Tsai MC, Kuo CE, Liu CT, Wu SY, Wu TC, Hung YC. 

Biomed J. 2021 May 1:S2319-4170(21)00042-1. doi: 10.1016/j.bj.2021.04.010. Epub ahead of print. PMID: 35595647.


Investigating Cognitive Functions in Methadone Users in Comparison with Methadone and Methamphetamine Users and Control Group. 

Eslami-Shahrbabaki M, Barfehee D, Parvaresh N, Zamani E, Soltaninejad A, Ahmadi A. 

Addict Health. 2022 Jan;14(1):1-6. doi: 10.22122/ahj.v14i1.292. PMID: 35573763; PMCID: PMC9057645.


Side Effects from Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements. 

Khalid K, Anuar A, Ang WC, Jamaluddin R. 

Curr Drug Saf. 2022 May 14. doi: 10.2174/1574886317666220514154931. Epub ahead of print. PMID: 35570535.



Identifying relative strength of methadone versus health and social services in comprehensive substance use disorder treatment using a variance decomposition approach. 

Shin HC, Marsh JC. 

Eval Program Plann. 2022 Feb 23;92:102060. doi: 10.1016/j.evalprogplan.2022.102060. Epub ahead of print. PMID: 35247677.


USA. Methadone: An American Way of Dealing (Video)

Klein and Richert’s camera contrasts a state-operated methadone clinic in Dayton, Ohio, with Washington, DC’s Afrocentric RAP therapeutic community, founded in 1970 by Ron Clark, a veteran of LA’s Synanon. (pointshistory.com, USA, 01.02.2022, Video, 01:05:56)


USA. The Points Methadone Marathon

Welcome to the home page for the Points Methadone Marathon! (pointshistory.com, USA, 01.02.2022)


The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14. 

Krebs E, Hongdilokkul N, Dale LM, Min JE, Schnepel KT, Shigeoka H, Nosyk B. 

J Subst Abuse Treat. 2021 Dec 28:108714. doi: 10.1016/j.jsat.2021.108714. Epub ahead of print. PMID: 35101357.


Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. 

Chawar C, Hillmer A, Lamri A, Kapczinski F, Thabane L, Pare G, et al. (2021) 

PLoS ONE 16(12): e0261201. doi.org/10.1371/journal.pone.0261201


Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT). 

Mahu IT, Barrett SP, Conrod PJ, Bartel SJ, Stewart SH. 

Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109133. doi: 10.1016/j.drugalcdep.2021.109133. Epub 2021 Oct 30. PMID: 34768142.


The influence of methadone on cerebral gray matter and functional connectivity. 

Zhu J, Wang S, Liu Y, Wang F, Li Q, Li Z, Sun Y, Li W, Wang W. 

Ann Palliat Med. 2021 Sep;10(9):9497-9507. doi: 10.21037/apm-21-2012. PMID: 34628875.


Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder? 

Kessler SH, Schwarz ES, Liss DB. 

J Med Toxicol. 2021 Sep 23. doi: 10.1007/s13181-021-00858-z. Epub ahead of print. PMID: 34554396.



Risk of motor vehicle collisions after methadone use. 

Yang YH, Ho PS, Wu TN, Wang PW, Lin CR, Tsai JH, Guo YL, Chuang HY. 

Elife. 2021 Aug 5;10:e63954. doi: 10.7554/eLife.63954. PMID: 34351275; PMCID: PMC8341976.


Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment. 

Huang CL, Chiang YC, Chang WC, Su YT, Yang JC, Cheng WC, Lane HY, Ho IK, Ma WL. 

Front Endocrinol (Lausanne). 2021 Aug 5;12:638884. doi: 10.3389/fendo.2021.638884. PMID: 34434167; PMCID: PMC8381776.


Gender disparities in opioid treatment progress in methadone versus counseling. 

Guerrero E, Amaro H, Kong Y, Khachikian T, Marsh JC. 

Subst Abuse Treat Prev Policy. 2021 Jun 23;16(1):52. doi: 10.1186/s13011-021-00389-4. PMID: 34162420; PMCID: PMC8220800.


Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.

Chalabianloo F, Fadnes LT, Høiseth G, Ohldieck C, Vold JH, Aas C, Løberg EM, Johansson KA, Bramness JG. 

Subst Abuse Treat Prev Policy. 2021 May 3;16(1):39. doi: 10.1186/s13011-021-00367-w. PMID: 33941217; PMCID: PMC8091668.


Differences in cue-induced brain activation between long-term methadone maintenance treatment and protracted abstinence in heroin use disorder patients: a functional magnetic resonance imaging study. 

Wei X, Li Q, Chen J, Shen B, Wang W, Li W. 

Quant Imaging Med Surg. 2021 May;11(5):2104-2113. doi: 10.21037/qims-20-1002. PMID: 33936991; PMCID: PMC8047338.


Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients. 

Delorme J, Pennel L, Brousse G, Daulouède JP, Delile JM, Lack P, Gérard A, Dematteis M, Kabore JL, Authier N, Chenaf C; TOXIDOL Study group. 

Front Psychiatry. 2021 Apr 26;12:641430. doi: 10.3389/fpsyt.2021.641430. PMID: 33981257; PMCID: PMC8107279.


ANDOPIO Study Group. Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders. 

Ruíz Ruíz JJ, Martinez Delgado JM, García-Marchena N; 

Harm Reduct J. 2021 Apr 13;18(1):41. doi: 10.1186/s12954-021-00488-2. PMID: 33849574; PMCID: PMC8042937.


Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy. 

Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R. 

J Pharm Bioallied Sci. 2020 Nov;12(Suppl 2):S787-S803. doi: 10.4103/jpbs.JPBS_248_19. Epub 2020 Nov 5. PMID: 33828379; PMCID: PMC8021064.


Gender Differences on Methadone Maintenance Treatment Outcome among Patients with Opioid use Disorder: A Systematic Review. 

Mohemmad Rizal MR, Hayat Khan A, Noor Harun S, Saleh Z. 

J Pharm Bioallied Sci. 2020 Nov;12(Suppl 2):S657-S662. doi: 10.4103/jpbs.JPBS_253_19. Epub 2020 Nov 5. PMID: 33828356; PMCID: PMC8021040.


Different formulations of methadone and levomethadone in the management of Opioid Use Disorder.

Somaini L., Vecchio S., Salvatore D.F., Ercolini A., and Leonardi C.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, March 18, 2021


Microdosing Case Study Series – Transferring from Methadone to Oral Buprenorphine

Cassells N., Hill D.R., Marr E., and Stewart E.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, December 4, 2020

Conclusions: The case studies demonstrate that the successful use of a microdose transition from methadone to oral buprenorphine is possible within a primary care setting with minimal side effects or discomfort and that this option could be explored further with other patients to improve therapeutic outcomes.


A case study of methadone-induced delayed post-hypoxic leukoencephalopathy with improvement by antioxidant therapy. 

Hakamifard A, Hajiahmadi S, Khorvash F, Azish S. 

North Clin Istanb. 2020 Aug 31;8(1):106-108. doi: 10.14744/nci.2020.29795. PMID: 33629035; PMCID: PMC7881437.


Reasons for Increasing Daily Methadone Maintenance Dosage among Deceptive Patients: A Qualitative Study. 

Khosravi M, Kasaeiyan R. 

J Med Life. 2020 Oct-Dec;13(4):572-579. doi: 10.25122/jml-2020-0038. PMID: 33456609; PMCID: PMC7803314.


Methadone Suppresses Neuronal Function and Maturation in Human Cortical Organoids. 

Wu W, Yao H, Dwivedi I, Negraes PD, Zhao HW, Wang J, Trujillo CA, Muotri AR, Haddad GG. 

Front Neurosci. 2020 Nov 23;14:593248. doi: 10.3389/fnins.2020.593248. PMID: 33328864; PMCID: PMC7719724.


From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia. 

Raski M, Sutherland C, Brar R. 

Can Fam Physician. 2020 Nov;66(11):797-798. PMID: 33208417.


The effect of methadone on depression among addicts: a systematic review and meta-analysis. 

Mohammadi M, Kazeminia M, Abdoli N, Khaledipaveh B, Shohaimi S, Salari N, Hosseinian-Far M. 

Health Qual Life Outcomes. 2020 Nov 23;18(1):373. doi: 10.1186/s12955-020-01599-3. PMID: 33225933; PMCID: PMC7681984.


The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment. 

Abbaszadeh-Mashkani S, Hoque SS, Banafshe HR, Ghaderi A. 

Phytother Res. 2020 Oct 19. doi: 10.1002/ptr.6913. Epub ahead of print. PMID: 33078480.



Toward patient-tailored therapy in agonist opioid treatment: the role of psychopathology, craving behavioural covariates, stress reaction and methadone blood concentration. A case series

Maremmani A.G.I., Bacciardi S., Maremmani I., Della Rocca F., Lamanna F., Socci C., Cerrai E., Zallocco L., Cerniglia L., Cimino S., Giusti L., Lucacchini A., Protti M., Mercolini L., Perugi G., and Mazzoni M.R.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, October 2, 2020


A mixed‐methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community‐based care in England and Wales. 

Gibson, R., MacLeod, N., Donaldson, L. J., Williams, H., Hibbert, P., Parry, G., Bhatt, J., Sheikh, A., and Carson‐Stevens, A. (2020) 

Addiction, 115: 2066– 2076. doi.org/10.1111/add.15039.